Frank nocturnal hypoglycaemia is accompanied by an increased cortisol to creatinine ratio in the early-morning urine specimen.3 We have therefore measured this ratio in insulintreated diabetic inpatients in whom nocturnal hypoglycaemia was not suspected. The results were used as a guide to insulin dosage in controlling fasting blood glucose values.
Patients and methods
Forty-three insulin-taking diabetic inptaients (26 men, 17 women) aged 17-73 years co-operated in the study. All were continent, and the duration of diabetes ranged from two to 23 years. Most were recovering from an operation (mainly amputation), though some were in hospital for stabilisation of their diabetes. All were taking a carbohydraterestricted diet, which included a snack at 10 pm. Throughout the trial the patients continued with their diets assessed by the dietitians. None of the patients had symptoms or signs suggestive of nocturnal hypoglycaemia.
The patients were studied for three to six days (mean five). After voiding urine at 10 pm they collected all their urine passed overnight; urine passed between 7 am and 12 noon was also collected. Blood for glucose measurement was taken at 7 am and 12 noon. Plasma glucose concentration, urinary glucose excretion, and urinary cortisol to creatinine ratios were measured daily, the cortisol to creatinine ratio being obtained by the early afternoon to permit alteration to treatment.
All patients entered the trial with normal cortisol to creatinine ratios3 -that is, below 55 x 10-6-and all were treated by increasing the long-acting component of their insulin dose-namely, the Lente, Monotard, or evening Isophane or Retard-in steps of about eight units. When the fasting plasma glucose concentration exceeded 12 mmol/l (216 mg/100 ml) the dosage was adjusted the same day, and when the concentration was 8-12 mmol/l (144-216 mg/100 ml) the dosage was adjusted on alternate days. Patients who never had a raised cortisol to creatinine ratio were treated in this way until the fasting plasma glucose concentration was 4-7 mmol/1 (72-126 mg/100 ml). Any patient whose ratio exceeded normal, thus suggesting hypoglycaemia, had the dosage of the long-acting component reduced immediately by 10-20 units, and if the ratio was still high the next day a similar reduction was made. As in patients with normal ratios, the aim was to achieve a fasting plasma glucose concentration of 4-7 mmol/l.
Laboratory methods-Plasma glucose concentration was measured by a glucose oxidase method using an ANALOX glucose analyser, and urinary glucose excretion was determined with Clinitest tablets and an appropriate dilution of urine. In the overnight urine sample creatinine was measured by the Jaffe reaction4 and cortisol by a specific radioimmunoassay kit (Eurotope Services Ltd, London).
Results with this kit are identical with those obtained with the competitive protein binding method5 (regression equation y= 1 05x -10; r< 0986, p = 0001; n = 40). Advantages, however, are shorter incubation times and shorter counting times for 125I-cortisol, which allow results to be produced within four hours. Statistical analysis was by Student's distribution or paired t test.
Results
Of the 43 patients, nine (group 1) had a raised cortisol to creatinine ratio detected at least once, and 34 (group 2) never had a raised ratio detected (table I) . There was no significant difference between the groups in age, sex distribution, or types of insulin used. Both total insulin dose and dose/kg body weight, however, were significantly higher in group 1.
The dose of long-acting insulin was reduced in the nine patients with presumptive nocturnal hypoglycaemia; in five, however, a further raised cortisol to creatinine ratio was detected and a second dose reduction was necessary. The detection of a raised cortisol to creatinine ratio in the overnight urine sample coincided with increases in plasma and urinary glucose concentrations which fell after reduction of the insulin dose ( 
Discussion
There was no definite evidence that the nine patients who had raised cortisol to creatinine ratios in their overnight urine samples had suffered nocturnal hypoglycaemia. The essential point is that their diabetic control improved dramatically with reduction in insulin dosage, which also reduced the cortisol to creatinine ratio to normal. The patients with normal cortisol to creatinine ratios, however, showed reductions in plasma glucose concentrations and urinary glucose excretion after increases in their insulin dosage, and their ratios never became high.
We do not believe that these findings are a consequence of a beneficial effect of increased length of stay in hospital because, as table II and the figure show, this was not so in those whose cortisol to creatinine ratios were still raised despite the first reduction in insulin dosage.
The patients with presumptive nocturnal hypoglycaemia received significantly higher total and long-acting insulin doses, though the mean insulin dose/kg body weight (101 U) was slightly less than that which produced hypoglycaemia in the Nottingham study (1 16 U).2 Our patients had appreciable urinary glucose losses (tables II and V), which continued the day after reducing the insulin dose and were associated with unacceptably high plasma glucose concentrations. Only on the second day after reducing the dose did plasma glucose concentration and urinary glucose excretion fall to acceptable values, which shows the severity and duration of the metabolic disturbance after unrecognised nocturnal hypoglycaemia.
Our aims of abolishing glycosuria and producing fasting plasma glucose concentrations of 4 to 7 mmol/l (72-126 mg/100 ml) were not achieved in all patients, because some left hospital before complete adjustment of their insulin dose had been made. Several patients still had unsatisfactory noon plasma glucose concentrations, indicating the need for additional "quick-acting" insulin in the morning. In our study 21 O/ of the patients suffered an episode of presumptive nocturnal hypoglycaemia, whereas Gale and Tattersall reported an incidence of 56,,2; the comparable mean reductions in insulin dose required for good diabetic control were 23oI and 250,. There is little information on the overall incidence of nocturnal hypoglycaemia in insulin-requiring diabetes, and both we and Gale and Tattersall2 in some way selected the subjects for study.
Our results strongly support the view that measuring the cortisol to creatinine ratio in an overnight urine specimen is a useful detector of an otherwise unrecognised nocturnal hypoglycaemic event. The test is straightforward and may be performed on a specimen collected by any co-operative continent patient, including outpatients. It provides a simple means of detecting poor glucose regulation caused by overtreatment with insulin and yields clear separation of normal and abnormal results. As well as serving as a guide to insulin treatment, it may elucidate how overtreatment with insulin causes unstable diabetes.
Several causes of false-positive results, however, will probably be recognised with continued study; Cushing's syndrome would be one cause, as would severe depression and a major physical upset such as nocturnal pulmonary embolism.
Ketotifen in adult asthma
A J DYSON, A D MACKAY Summary and conclusions The efficacy and adverse effects of ketotifen 1 mg twice daily and 2 mg twice daily were compared with placebo in 50 patients with atopic asthma in a multicentre, double-blind study. Ketotifen in the higher dosage caused a slight reduction in salbutamol usage and a modest improvement in breathing in patients not already receiving inhaled corticosteroids. The drug was ineffective in patients receiving inhaled corticosteroids. Drowsiness was a troublesome effect causing withdrawal from treatment or reduction of dosage in seven patients while receiving ketotifen compared with only three while receiving placebo. Thus the slight beneficial effect of ketotifen on asthma must be balanced against its side effect of drowsiness.
Introduction
Sodium cromoglycate benefits asthmatic patients.' Oral antiallergic compounds that like cromoglycate inhibit anaphylactic mediator release in laboratory models have now been synthesised. These might benefit patients unable to use an inhaler efficiently. One of these compounds, ketotifen, is a benzocycloheptathiophene derivative that shows potent antianaphylactic and antihistaminic activity in animals. Ketotifen also inhibits chemically induced release of histamine from rat peritoneal mast cells by compound 48/80 in vitro.2 Oral ketotifen has shown a protective effect against allergen-induced bronchoconstriction in adults with atopic asthma3 but not in children. 4 We report a longerterm comparison of ketotifen and placebo in adult asthma.
Patients and methods
We recruited 50 patients (34 men and 16 women) aged 16-66 years (mean age 36 years) from 12 centres. All had a forced expiratory volume in one second (FEV,) above 40%, of their predicted value, reacted to skin-prick tests with common allergens, and showed a greater than 20%' improvement in FEV, after inhaling a bronchodilator. Patients taking tablets of corticosteroid were excluded, but those who inhaled a constant dosage of corticosteroid were included. Patients in whom the potential effect of drowsiness might have proved dangerous were not eligible. Sodium cromoglycate was not permitted during the four weeks before entry. Bronchodilators other than inhaled salbutamol for symptomatic relief were stopped.
